NEW YORK (GenomeWeb) – MolecularMD has partnered with Asterand Bioscience to provide its biopharma customers with an end-to-end workflow for biomarker and cancer drug target validation, and assay development, the companies announced today.

Under the terms of the deal, MolecularMD will access Asterand's human tissue procurement, characterization, and research services to assist with the development of custom clinical trial assays and companion diagnostic products for its clients. Specific details were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.